MYD88 and adenocarcinoma: In this work, we studied the mechanism of action and antitumor efficacy of a cell-based virotherapy using MSCs knockout for TLR4−/− (OAd-MSC TLR4−/−) and MSCs knockout for MyD88−/− (OAd-MSC MyD88−/−) as “silent cells” in an immunocompetent mouse model of adenocarcinoma, in comparison with the use of MSCs wildtype (OAd-MSC WT).